MBX Biosciences, Inc.
MBX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001776111
In the last 90 days, MBX Biosciences, Inc. insiders filed 0 open-market purchases and 1 sale; 172 institutions reported holding it in 13F filings for Q2 2026, worth $3.06B in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in MBX Biosciences, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 118
- +30 vs. Q2 2025
- Shares held
- 47.8M
- +11.0M (+29.7%) vs. Q2 2025
- Total value
- $836.4M
- +$416.0M (+99.0%) vs. Q2 2025
- New holders
- 39
- 29 more added
- Sold out
- 9
- 30 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting MBX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 172 | $3.06B |
| Q1 2026 | 157 | $1.57B |
| Q4 2025 | 138 | $1.53B |
| Q3 2025 | 118 | $836.4M |
| Q2 2025 | 88 | $420.3M |
| Q1 2025 | 79 | $263.2M |
| Q4 2024 | 63 | $606.5M |
| Q3 2024 | 45 | $784.1M |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding MBX Biosciences, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Millennium Management LLC | 655,416 | $11.5M | 0.01% | −111,424−14.5% | Reduced |
| Parkman Healthcare Partners LLC | 773,304 | $13.5M | 1.49% | −98,629−11.3% | Reduced |
| Price T Rowe Associates Inc | 954,726 | $16.7M | 0.00% | −392,184−29.1% | Reduced |
| Citadel Advisors LLC | 996,083 | $17.4M | 0.01% | +996,083 | New |
| Woodline Partners LP | 1,201,150 | $21.0M | 0.10% | +300,047+33.3% | Added |
| Cormorant Asset Management, LP | 1,225,000 | $21.4M | 1.48% | +525,000+75.0% | Added |
| Franklin Resources Inc | 1,307,288 | $22.9M | 0.01% | +812,436+164.2% | Added |
| Driehaus Capital Management LLC | 1,539,639 | $26.9M | 0.19% | −32,267−2.1% | Reduced |
| Vanguard Group Inc | 1,677,362 | $29.4M | 0.00% | +633,678+60.7% | Added |
| BlackRock, Inc. | 1,957,461 | $34.3M | 0.00% | +945,915+93.5% | Added |
| Kynam Capital Management, LP | 2,000,000 | $35.0M | 2.61% | +2,000,000 | New |
| EcoR1 Capital, LLC | 2,123,604 | $37.2M | 1.79% | +973,810+84.7% | Added |
| NVP Associates, LLC | 2,136,335 | $37.4M | 22.51% | 00.0% | Unchanged |
| Deep Track Capital, LP | 3,150,000 | $55.1M | 1.54% | +961,408+43.9% | Added |
| NEA Management Company, LLC | 3,614,486 | $63.3M | 3.47% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 4,002,887 | $70.1M | 1.68% | 00.0% | Unchanged |
| Wellington Management Group LLP | 4,823,336 | $84.4M | 0.01% | +2,556,708+112.8% | Added |
| Frazier Life Sciences Management, L.P. | 6,652,013 | $116.4M | 3.49% | +666,666+11.1% | Added |
| MPM Oncology Impact Management LP | 0 | $0 | 0.00% | −1,294,416−100.0% | Sold out |
| Ra Capital Management, L.P. | 0 | $0 | 0.00% | −377,841−100.0% | Sold out |
| Sio Capital Management, LLC | 0 | $0 | 0.00% | −241,000−100.0% | Sold out |
| Resolute Capital Asset Partners LLC | 0 | $0 | 0.00% | −49,670−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −27,632−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −15,617−100.0% | Sold out |
| Intech Investment Management LLC | 0 | $0 | 0.00% | −14,271−100.0% | Sold out |
| Raymond James Financial Inc | 0 | $0 | 0.00% | −761−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −411−100.0% | Sold out |